<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34563706</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><Volume>112</Volume><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Mast cell activation symptoms are prevalent in Long-COVID.</ArticleTitle><Pagination><StartPage>217</StartPage><EndPage>226</EndPage><MedlinePgn>217-226</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2021.09.043</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(21)00751-7</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Hyper-inflammation caused by COVID-19 may be mediated by mast cell activation (MCA) which has also been hypothesized to cause Long-COVID (LC) symptoms. We determined prevalence/severity of MCA symptoms in LC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Adults in LC-focused Facebook support groups were recruited for online assessment of symptoms before and after COVID-19. Questions included presence and severity of known MCA and LC symptoms and validated assessments of fatigue and quality of life. General population controls and mast cell activation syndrome (MCAS) patients were recruited for comparison if they were &#x2265;18 years of age and never had overt COVID-19 symptoms.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 136 LC subjects (89.7% females, age 46.9 &#xb1;12.9 years), 136 controls (65.4% females, age 49.2 &#xb1;15.5), and 80 MCAS patients (85.0% females, age 47.7 &#xb1;16.4). Pre-COVID-19 LC subjects and controls had virtually identical MCA symptom and severity analysis. Post-COVID-19 LC subjects and MCAS patients prior to treatment had virtually identical MCA symptom and severity analysis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">MCA symptoms were increased in LC and mimicked the symptoms and severity reported by patients who have MCAS. Increased activation of aberrant mast cells induced by SARS-CoV-2 infection by various mechanisms may underlie part of the pathophysiology of LC, possibly suggesting routes to effective therapy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weinstock</LastName><ForeName>Leonard B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Associate Professor of Clinical Medicine, Departments of Medicine, Missouri Baptist Medical Center and Washington University School of Medicine, President, Specialists in Gastroenterology, 11525 Olde Cabin Road, St. Louis, MO, USA 63141, TEL 314-997-4627, FAX 314-997-5086. Electronic address: lw@gidoctor.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brook</LastName><ForeName>Jill B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Biostatistics, Private Practice, 13285 Roundhill, Truckee, CA, USA 96161, TEL 626-375-6725. Electronic address: jillbrook@msn.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walters</LastName><ForeName>Arthur S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Professor of Neurology, Division of Sleep Medicine, Vanderbilt University School of Medicine, Medical Center North A-0118, 1161 21(st) Ave South, Nashville, TN, USA 37232-2551, TEL 615-322-0283, FAX 615- 936-5663. Electronic address: art.walters@vumc.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goris</LastName><ForeName>Ashleigh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Manager, Infection Prevention &amp; Control and Clinical Quality, Missouri Baptist Medical Center, Mailstop: 95, 3015 N. Ballas Road, St. Louis, MO, USA 63131, TEL 314-996-5421, FAX 314-996-5909. Electronic address: Ashleigh.goris@Mercy.Net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afrin</LastName><ForeName>Lawrence B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Department of Mast Cell Studies, Hematology/Oncology, AIM Center for Personalized Medicine, Purchase, NY, USA 10577, TEL 914-730-7390, FAX 914-730-7391. Electronic address: drafrin@aimcenterpm.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molderings</LastName><ForeName>Gerhard J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Associate Professor of Pharmacology and Toxicology, Molecular Geneticist, Immunologist, Institute of Human Genetics, University Hospital Bonn, D53127 Bonn, Germany, TEL ++49 1623322001, FAX ++49 2225 9984911. Electronic address: molderings@uni-bonn.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090267" MajorTopicYN="Y">Mast Cell Activation Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008407" MajorTopicYN="N">Mast Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">fatigue</Keyword><Keyword MajorTopicYN="N">mast cell activation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>26</Day><Hour>20</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34563706</ArticleId><ArticleId IdType="pmc">PMC8459548</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2021.09.043</ArticleId><ArticleId IdType="pii">S1201-9712(21)00751-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Afrin L.B., Butterfield J.H., Raithel M., Molderings G.J. Often seen, rarely recognized: mast cell activation disease&#x2013;a guide to diagnosis and therapeutic options. Review article. Ann Med. 2016;48:190&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">27012973</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin L.B., Cichocki F., Hoeschen A., Beckman K.B., Gupta K., Nguyen J., et al. Mast cell regulatory gene variants are common in mast cell activation syndrome. Blood. 2016;128(22):4878. doi: 10.1182/blood.V128.22.4878.4878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V128.22.4878.4878</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin L.B., Self S., Menk J., Lazarchick J. Characterization of mast cell activation syndrome. Am J Med Sci. 2017;353(3):207&#x2013;215. doi: 10.1016/j.amjms.2016.12.013. Mar PMID: 28262205; PMCID: PMC5341697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjms.2016.12.013</ArticleId><ArticleId IdType="pmc">PMC5341697</ArticleId><ArticleId IdType="pubmed">28262205</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin L.B., Ackerley M.B., Bluestein L.S., Brewer J.H., Brook J.B., Buchanan A.D., et al. Diagnosis of mast cell activation syndrome: a global "consensus-2". Diagnosis (Berl) 2020;8(2):137&#x2013;152. doi: 10.1515/dx-2020-0005. PMID: 32324159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/dx-2020-0005</ArticleId><ArticleId IdType="pubmed">32324159</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin L.B., Weinstock L.B., Molderings G.J. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7529115</ArticleId><ArticleId IdType="pubmed">32920235</ArticleId></ArticleIdList></Reference><Reference><Citation>Altm&#xfc;ller J., Haenisch B., Kawalia A., Menzen M., N&#xf6;then M.M., Fier H., et al. Mutational profiling in the peripheral blood leukocytes of patients with systemic mast cell activation syndrome using next-generation sequencing. Immunogenetics. 2017;69(6):359&#x2013;369. doi: 10.1007/s00251-017-0981-y. PMID: 28386644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00251-017-0981-y</ArticleId><ArticleId IdType="pubmed">28386644</ArticleId></ArticleIdList></Reference><Reference><Citation>Balestroni G., Bertolotti G. L'EuroQol-5D (EQ-5D): uno strumento per la misura della qualit&#xe0; della vita [EuroQol-5D (EQ-5D): an instrument for measuring quality of life] Monaldi Arch Chest Dis. 2012;78(3):155&#x2013;159. doi: 10.4081/monaldi.2012.121. PMID: 23614330.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/monaldi.2012.121</ArticleId><ArticleId IdType="pubmed">23614330</ArticleId></ArticleIdList></Reference><Reference><Citation>Barr&#xe9; J., Sabatier J.M., Annweiler C. Montelukast drug may improve COVID-19 prognosis: a review of evidence. Front Pharmacol. 2020;11:1344. doi: 10.3389/fphar.2020.01344. PMID: 33013375; PMCID: PMC7500361.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.01344</ArticleId><ArticleId IdType="pmc">PMC7500361</ArticleId><ArticleId IdType="pubmed">33013375</ArticleId></ArticleIdList></Reference><Reference><Citation>Choubey A., Dehury B., Kumar S., Medhi B., Mondal P. Naltrexone a potential therapeutic candidate for COVID-19. J Biomol Struct Dyn. 2020;15:1&#x2013;8. doi: 10.1080/07391102.2020.1820379. PMID: 32930058; PMCID: PMC7544934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1820379</ArticleId><ArticleId IdType="pmc">PMC7544934</ArticleId><ArticleId IdType="pubmed">32930058</ArticleId></ArticleIdList></Reference><Reference><Citation>Colunga Biancatelli R.M.L., Berrill M., Catravas J.D., Marik P.E. Quercetin and vitamin C: an experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related disease (COVID-19) Front Immunol. 2020;11:1451. doi: 10.3389/fimmu.2020.01451. PMID: 32636851; PMCID: PMC7318306.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01451</ArticleId><ArticleId IdType="pmc">PMC7318306</ArticleId><ArticleId IdType="pubmed">32636851</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re'em Y., et al. Characterizing long Covid in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021 doi: 10.1016/j.eclinm.2021.101019. (Last accessed 8/14/21)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vries J., Michielsen H.J., Van Heck G.L. Assessment of fatigue among working people: a comparison of six questionnaires. Occup Environ Med. 2003;60(Suppl 1) doi: 10.1136/oem.60.suppl_1.i10. i10-5PMID: 12782741; PMCID: PMC1765720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/oem.60.suppl_1.i10</ArticleId><ArticleId IdType="pmc">PMC1765720</ArticleId><ArticleId IdType="pubmed">12782741</ArticleId></ArticleIdList></Reference><Reference><Citation>FAIR Health White Paper. A detailed study of patients with long-haul COVID. https://s3.amazonaws.com/media2.fairhealth.org/whitepaper/asset/A%20Detailed%20Study%20of%20Patients%20with%20Long-Haul%20COVID&#x2013;An%20Analysis%20of%20Private%20Healthcare%20Claims&#x2013;A%20FAIR%20Health%20White%20Paper.pdf. June 15, 2021. (Last accessed 8/14/21).</Citation></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C., Palacios-Ce&#xf1;a D., G&#xf3;mez-Mayordomo V., Rodr&#xed;uez-Jim&#xe9;nez J., Palacios-Ce&#xf1;a M., Velasco-Arribas M., et al. Long-term post-COVID symptoms and associated risk factors in previously hospitalized patients: A multicenter study. J Infect. 2021 doi: 10.1016/j.jinf.2021.04.036. S0163-4453(21)00223-1PMID: 33984399; PMCID: PMC8110627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.04.036</ArticleId><ArticleId IdType="pmc">PMC8110627</ArticleId><ArticleId IdType="pubmed">33984399</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedberg D.E., Conigliaro J., Wang T.C., Tracey K.J., Callahan M.V., Abrams J.A. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study. Gastroenterology. 2020;159:1129&#x2013;1131. doi: 10.1053/j.gastro.2020.05.053. PMID: 32446698 PMCID: PMC7242191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.053</ArticleId><ArticleId IdType="pmc">PMC7242191</ArticleId><ArticleId IdType="pubmed">32446698</ArticleId></ArticleIdList></Reference><Reference><Citation>Gigante A., Aquili A., Farinelli L., Caraffa A., Ronconi G., Enrica Gallenga C., et al. Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19. Med Hypotheses. 2020;143 doi: 10.1016/j.mehy.2020.109856. PMID: 32460208; PMCID: PMC7236677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.109856</ArticleId><ArticleId IdType="pmc">PMC7236677</ArticleId><ArticleId IdType="pubmed">32460208</ArticleId></ArticleIdList></Reference><Reference><Citation>Haenisch B., N&#xf6;then M.M., Molderings G.J. Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics. Immunology. 2012;137(3):197&#x2013;205. doi: 10.1111/j.1365-2567.2012.03627.x. PMID: 22957768; PMCID: PMC3482677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2012.03627.x</ArticleId><ArticleId IdType="pmc">PMC3482677</ArticleId><ArticleId IdType="pubmed">22957768</ArticleId></ArticleIdList></Reference><Reference><Citation>Haenisch B., Fr&#xf6;hlich H., Herms S., Molderings G.J. Evidence for contribution of epigenetic mechanisms in the pathogenesis of systemic mast cell activation disease. Immunogenetics. 2014;66(5):287&#x2013;297. doi: 10.1007/s00251-014-0768-3. PMID: 24622794.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00251-014-0768-3</ArticleId><ArticleId IdType="pubmed">24622794</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendriks C., Drent M., Elfferich M., De Vries J. The fatigue assessment scale: quality and availability in sarcoidosis and other diseases. Curr Opin Pulm Med. 2018;24(5):495&#x2013;503. doi: 10.1097/MCP.0000000000000496. PMID: 29889115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCP.0000000000000496</ArticleId><ArticleId IdType="pubmed">29889115</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan R.B., II, Hogan R.B., III, Cannon T., Rappai M., Studdard S., Paul D., et al. Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. Pulm Pharm Ther. 2020;63 doi: 10.1016/j.pupt.2020.101942. ISSN 1094-5539PMID: 32871242; PMCID: PMC7455799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pupt.2020.101942</ArticleId><ArticleId IdType="pmc">PMC7455799</ArticleId><ArticleId IdType="pubmed">32871242</ArticleId></ArticleIdList></Reference><Reference><Citation>Janowitz T., Gablenz E., Pattinson D., Wang T.C., Conigliaro J., Tracey K., et al. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut. 2020;69:1592&#x2013;1597. doi: 10.1136/gutjnl-2020-321852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-321852</ArticleId><ArticleId IdType="pmc">PMC7299656</ArticleId><ArticleId IdType="pubmed">32499303</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazama I. Stabilizing mast cells by commonly used drugs: a novel therapeutic target to relieve post-COVID syndrome? Drug Discov Ther. 2020;14(5):259&#x2013;261. doi: 10.5582/ddt.2020.03095. PMID: 33116043.</Citation><ArticleIdList><ArticleId IdType="doi">10.5582/ddt.2020.03095</ArticleId><ArticleId IdType="pubmed">33116043</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempuraj D., Selvakumar G.P., Ahmed M.E., Raikwar S.P., Thangavel R., Khan A., et al. COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation. Neuroscientist. 2020;26(5-6):402&#x2013;414. doi: 10.1177/1073858420941476. PMID: 32684080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858420941476</ArticleId><ArticleId IdType="pubmed">32684080</ArticleId></ArticleIdList></Reference><Reference><Citation>Koupenova M., Freedman J.E. Platelets and COVID-19: inflammation, hyperactivation and additional questions. Circ Res. 2020;127(11):1419&#x2013;1421. doi: 10.1161/CIRCRESAHA.120.318218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.318218</ArticleId><ArticleId IdType="pmc">PMC7641185</ArticleId><ArticleId IdType="pubmed">33151798</ArticleId></ArticleIdList></Reference><Reference><Citation>Kritas S.K., Ronconi G., Caraffa A., Gallenga C.E., Ross R., Conti P. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J Biol Regul Homeost Agents. 2020;34(1):9&#x2013;14. doi: 10.23812/20-editorial-kritas. PMID: 32013309.</Citation><ArticleIdList><ArticleId IdType="doi">10.23812/20-editorial-kritas</ArticleId><ArticleId IdType="pubmed">32013309</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Sawalha A.H., Qianjin Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33:155&#x2013;162. doi: 10.1097/BOR.0000000000000776. PMID: 33332890; PMCID: PMC7880581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000776</ArticleId><ArticleId IdType="pmc">PMC7880581</ArticleId><ArticleId IdType="pubmed">33332890</ArticleId></ArticleIdList></Reference><Reference><Citation>Mather J.F., Seip R.L., McKay R.G. Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19. Am J Gastroenterol. 2020;115(10):1617&#x2013;1623. doi: 10.14309/ajg.0000000000000832. PMID: 32852338; PMCID: PMC7473796.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000000832</ArticleId><ArticleId IdType="pmc">PMC7473796</ArticleId><ArticleId IdType="pubmed">32852338</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxwell A.J., Ding J., You Y., Dong Z., Chehade H., Alvero A., et al. Identification of key signaling pathways induced by SARS-CoV2 that underlie thrombosis and vascular injury in COVID-19 patients. J Leukoc Biol. 2021;109:35&#x2013;47. doi: 10.1002/JLB.4COVR0920-552RR. PMID: 33242368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.4COVR0920-552RR</ArticleId><ArticleId IdType="pmc">PMC7753679</ArticleId><ArticleId IdType="pubmed">33242368</ArticleId></ArticleIdList></Reference><Reference><Citation>Molderings G.J., Kolck U., Scheurlen C., Br&#xfc;ss M., Frieling T., Raithel M., Homann J. Die systemische Mastzellerkrankung mit gastrointestinal betonter Symptomatik&#x2013;eine Checkliste als Diagnoseinstrument [Systemic mast cell disease with gastrointestinal symptoms&#x2013;a diagnostic questionnaire] Dtsch Med Wochenschr. 2006;131(38):2095&#x2013;2100. doi: 10.1055/s-2006-951337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2006-951337</ArticleId><ArticleId IdType="pubmed">16981082</ArticleId></ArticleIdList></Reference><Reference><Citation>Molderings G.J., Kolck U.W., Scheurlen C., Br&#xfc;ss M., Homann J., Von K&#xfc;gelgen I. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand J Gastroenterol. 2007;42(9):1045&#x2013;1053. doi: 10.1080/00365520701245744. PMID: 17710669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365520701245744</ArticleId><ArticleId IdType="pubmed">17710669</ArticleId></ArticleIdList></Reference><Reference><Citation>Molderings G.J., Meis K., Kolck U.W., Homann J., Frieling T. Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects. Immunogenetics. 2010;62(11-12):721&#x2013;727. doi: 10.1007/s00251-010-0474-8. PMID: 20838788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00251-010-0474-8</ArticleId><ArticleId IdType="pubmed">20838788</ArticleId></ArticleIdList></Reference><Reference><Citation>Molderings G.J., Haenisch B., Bogdanow M., Fimmers R., N&#xf6;then M.M. Familial occurrence of systemic mast cell activation disease. PLoS One. 2013;8(9):e76241. doi: 10.1371/journal.pone.0076241. PMID: 24098785; PMCID: PMC3787002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0076241</ArticleId><ArticleId IdType="pmc">PMC3787002</ArticleId><ArticleId IdType="pubmed">24098785</ArticleId></ArticleIdList></Reference><Reference><Citation>Molderings G.J. The genetic basis of mast cell activation disease - looking through a glass darkly. Crit Rev Oncol Hematol. 2015;93(2):75&#x2013;89. doi: 10.1016/j.critrevonc.2014.09.001. PMID: 25305106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2014.09.001</ArticleId><ArticleId IdType="pubmed">25305106</ArticleId></ArticleIdList></Reference><Reference><Citation>Molderings G.J. Transgenerational transmission of systemic mast cell activation disease-genetic and epigenetic features. Transl Res. 2016;174:86&#x2013;97. doi: 10.1016/j.trsl.2016.01.001. PMID: 26880691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2016.01.001</ArticleId><ArticleId IdType="pubmed">26880691</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee R., Bhattacharya A., Bojkova D., Mehdipour A.R., Shin D., Khan K.S., et al. Famotidine inhibits Toll-like receptor 3-mediated inflammatory signaling in SARS-CoV2 infection. J Biol Chem. 2021 Jun 29 doi: 10.1016/j.jbc.2021.100925. PMID: 34214498; PMCID: PMC8241579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100925</ArticleId><ArticleId IdType="pmc">PMC8241579</ArticleId><ArticleId IdType="pubmed">34214498</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit D., Bobkov P., Spiridonova E., Shikhaleva A., Gamirova A., Blyuss O., et&#xa0;al. Risk factors for long-term consequences of COVID-19 in hospitalised adults in Moscow using the ISARIC Global follow-up protocol: StopCOVID cohort study. medRxiv 2021.02.17.21251895. doi: 10.1101/2021.02.17.21251895.</Citation></Reference><Reference><Citation>Patterson T., Isales C.M., Fulzele S. Low level of vitamin C and dysregulation of vitamin C transporter might be involved in the severity of COVID-19 Infection. Aging Dis. 2021;12(1):14&#x2013;26. doi: 10.14336/AD.2020.0918. PMID: 33532123; PMCID: PMC7801272.</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2020.0918</ArticleId><ArticleId IdType="pmc">PMC7801272</ArticleId><ArticleId IdType="pubmed">33532123</ArticleId></ArticleIdList></Reference><Reference><Citation>Perricone C., Bartoloni E., Bursi R., Cafaro G., Guidelli G.M., Shoenfeld Y., Gerl R. COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. Immunol Res. 2020;68(4):213&#x2013;224. doi: 10.1007/s12026-020-09145-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-020-09145-5</ArticleId><ArticleId IdType="pmc">PMC7366458</ArticleId><ArticleId IdType="pubmed">32681497</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinheiro M.M., Fabbri A., Infante M. Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i) Immunotherapy. 2021;13(9):753&#x2013;765. doi: 10.2217/imt-2020-0349. PMID: 33906375; PMCID: PMC8080872.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/imt-2020-0349</ArticleId><ArticleId IdType="pmc">PMC8080872</ArticleId><ArticleId IdType="pubmed">33906375</ArticleId></ArticleIdList></Reference><Reference><Citation>Stulpin C. Long COVID: A &#x2018;mysterious&#x2019; syndrome with &#x2018;no clear pattern&#x2019; of symptoms. https://www.healio.com/news/infectious-disease/20210713/long-covid-a-mysterious-syndrome-with-no-clear-pattern-of-symptoms. July 21, 2021. (Last accessed 8/14/21).</Citation></Reference><Reference><Citation>Talkington J., Nickell S.P. Borrelia burgdorferi spirochetes induce mast cell activation and cytokine release. Infect Immun. 1999;67(3):1107&#x2013;1115. doi: 10.1128/IAI.67.3.1107-1115.1999. PMID: 10024550; PMCID: PMC96436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.67.3.1107-1115.1999</ArticleId><ArticleId IdType="pmc">PMC96436</ArticleId><ArticleId IdType="pubmed">10024550</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides T.C., Tsilioni I., Ren H. Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders? Expert Rev Clin Immunol. 2019;15(6):639&#x2013;656. doi: 10.1080/1744666X.2019.1596800. Jun Epub 2019 Apr 22. PMID: 30884251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2019.1596800</ArticleId><ArticleId IdType="pmc">PMC7003574</ArticleId><ArticleId IdType="pubmed">30884251</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides T.C. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. Biofactors. 2020;46(3):306&#x2013;308. doi: 10.1002/biof.1633. PMID: 32339387; PMCID: PMC7267424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1633</ArticleId><ArticleId IdType="pmc">PMC7267424</ArticleId><ArticleId IdType="pubmed">32339387</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides T.C, Conti P. COVID-19 and multisystem inflammatory syndrome, or is it mast cell activation syndrome? J Biol Regul Homeost Agents. 2020;34(5):1633&#x2013;1636. doi: 10.23812/20-EDIT3. PMID: 33023287.</Citation><ArticleIdList><ArticleId IdType="doi">10.23812/20-EDIT3</ArticleId><ArticleId IdType="pubmed">33023287</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides TC, Cholevas C, Polyzoidis K, Politis A. Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue. Biofactors. 2021;47(2):232&#x2013;241. doi: 10.1002/biof.1726. Mar Epub 2021 Apr 12. PMID: 33847020; PMCID: PMC8250989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1726</ArticleId><ArticleId IdType="pmc">PMC8250989</ArticleId><ArticleId IdType="pubmed">33847020</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides T.C. Potential association of mast cells with coronavirus disease 2019. Ann Allergy Asthma Immunol. 2021;126(3):217&#x2013;218. doi: 10.1016/j.anai.2020.11.003. PMID: 33161155; PMCID: PMC7644430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anai.2020.11.003</ArticleId><ArticleId IdType="pmc">PMC7644430</ArticleId><ArticleId IdType="pubmed">33161155</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojdani A., Vojdani E., Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol. 2021;11 doi: 10.3389/fimmu.2020.617089.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.617089</ArticleId><ArticleId IdType="pmc">PMC7873987</ArticleId><ArticleId IdType="pubmed">33584709</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng Z, Patel AB, Panagiotidou S, Theoharides TC. The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. J Allergy Clin Immunol. 2015;135(4) doi: 10.1016/j.jaci.2014.10.032. Apr 1044-1052.e5Epub 2014 Dec 10. PMID: 25498791; PMCID: PMC4388775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2014.10.032</ArticleId><ArticleId IdType="pmc">PMC4388775</ArticleId><ArticleId IdType="pubmed">25498791</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock L.B., Pace L.A., Rezaie A., Afrin L.B., Molderings G.J. Mast cell activation syndrome: a primer for the gastroenterologist. Dig Dis Sci. 2021;66(4):965&#x2013;982. doi: 10.1007/s10620-020-06264-9. PMID: 32328892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-020-06264-9</ArticleId><ArticleId IdType="pubmed">32328892</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong S.J. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond) 2021:1&#x2013;18. doi: 10.1080/23744235.2021.1924397. PMID: 34024217; PMCID: PMC8146298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock L.B., Blasingame K. Low dose naltrexone and gut health. In: Elsegood L., (Ed.) The LDN Book Volume 2. Vermont: Chelsea Green Publishing. 2020. p. 35&#x2013;54.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>